This market insight provides a first-of-its-kind analysis of market sizing and revenue forecasts through 2016 for the prevalent Ebola virus. The number of people infected nears 10,000 globally, and the Centers for Disease Control and Prevention (CDC) and World Health Organization (WHO) have deemed this the worst outbreak due to the death toll nearing 5,000. The Ebola market is segmented by diagnostics and pharmaceuticals, and the diagnostics market includes both molecular methods and immunodiagnostics tests, of which a 2-year potential-revenue forecast is provided. Molecular methods will see wide adoption for the specificity, sensitivity, and rapidity of the tests. Competitive landscape and companies to watch chapters are provided.
Table of Contents
Executive SummaryKey FindingsMarket OverviewWhat is Ebola?Timeline of Key Events Scope and SegmentationKey Questions This Study Will AnswerCEO’s PerspectiveSpread of EbolaMethodology, Assumptions, and DefinitionsMethodology, Assumptions, and Definitions (continued)Methodology, Assumptions, and Definitions (continued)Methodology, Assumptions, and Definitions (continued)Projected Ebola Prevalence (Global) Ebola Market for Molecular Tests (Global) Ebola Market for Immunodiagnostic Tests (Global) Global Expenditure Forecast by Mild Cases of EbolaGlobal Expenditure Forecast by Severe Cases of EbolaGlobal Expenditure Forecast Comparing Mild and Severe Ebola Cases Competitive LandscapeCompetitive Landscape for Pipeline Vaccines and DrugsCompetitive Landscape for Diagnostic ProductsCompanies to WatchEbola DiagnosticsEbola Drugs and VaccinesLegal DisclaimerThe Frost & Sullivan StoryThe Frost & Sullivan StoryValue Proposition—Future of Your Company & CareerGlobal PerspectiveIndustry Convergence360º Research PerspectiveImplementation ExcellenceOur Blue Ocean Strategy